Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
This suggests the peptide may have cardioprotective properties, though human data remains limited
Common Mistakes to Avoid Avoid inconsistent use, skipping sunscreen, combining duplicate nutrients and expecting instant results
Key Clinical Data (Authoritative Research) - Obesity: 28.7% average weight loss over 68 weeks (TRIUMPH-4 Study) - 12 mg dose: 17.5% weight loss (24w), 24.2% (48w) - Diabetes: Improves glycemic control, safety similar to GLP-1 RAs Molecular Design Highlights - GIP peptide backbone (39 amino acids), ~6-day half-life, good adherence - Special modifications: enhanced stability, long-acting, suitable for long-term use Research Focus Populations - Adults with type 2 diabetes (with diet/exercise) - Adults with obesity/overweight + weight-related comorbidities Industry Significance From single/dual-target to triple agonist, Retatrutide leads metabolic drug research, redefining diabetes/obesity research paradigms
Whether any of these compounds is right for you specifically
